[go: up one dir, main page]

MA31949B1 - Dérivés d'aminotriazole comme agonistes d'alx - Google Patents

Dérivés d'aminotriazole comme agonistes d'alx

Info

Publication number
MA31949B1
MA31949B1 MA32968A MA32968A MA31949B1 MA 31949 B1 MA31949 B1 MA 31949B1 MA 32968 A MA32968 A MA 32968A MA 32968 A MA32968 A MA 32968A MA 31949 B1 MA31949 B1 MA 31949B1
Authority
MA
Morocco
Prior art keywords
alx
antagonist
aminotriazole derivatives
derivatives act
aminotriazole
Prior art date
Application number
MA32968A
Other languages
Arabic (ar)
English (en)
Inventor
Daniel Bur
Sylvaine Cren
Olivier Corminboeuf
Corinna Grisostomi
Xavier Leroy
Sylvia Richard-Bildstein
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA31949B1 publication Critical patent/MA31949B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des dérivés d'aminotriazole de la formule (i), dans laquelle a, e, r1 et r2 sont tels que définis dans la description, ainsi que leur préparation et leur utilisation comme composés pharmaceutiquement actifs. Les composés sont utiles pour la prévention ou le traitement de maladies qui répondent à la modulation du récepteur alx telles que des maladies inflammatoires.
MA32968A 2007-12-18 2010-06-29 Dérivés d'aminotriazole comme agonistes d'alx MA31949B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2007055199 2007-12-18
IB2008054369 2008-10-23
PCT/IB2008/055375 WO2009077990A1 (fr) 2007-12-18 2008-12-17 Dérivés d'aminotriazole comme agonistes d'alx

Publications (1)

Publication Number Publication Date
MA31949B1 true MA31949B1 (fr) 2010-12-01

Family

ID=40404773

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32968A MA31949B1 (fr) 2007-12-18 2010-06-29 Dérivés d'aminotriazole comme agonistes d'alx

Country Status (25)

Country Link
US (1) US8536209B2 (fr)
EP (1) EP2225231B1 (fr)
JP (1) JP4656674B2 (fr)
KR (1) KR101213007B1 (fr)
CN (1) CN101903378B (fr)
AR (1) AR069801A1 (fr)
AT (1) ATE520689T1 (fr)
AU (1) AU2008337097B2 (fr)
BR (1) BRPI0821115A8 (fr)
CA (1) CA2706839C (fr)
CY (1) CY1112465T1 (fr)
DK (1) DK2225231T3 (fr)
HR (1) HRP20110825T1 (fr)
IL (1) IL206399A (fr)
MA (1) MA31949B1 (fr)
MX (1) MX2010006241A (fr)
MY (1) MY153985A (fr)
NZ (1) NZ586735A (fr)
PL (1) PL2225231T3 (fr)
PT (1) PT2225231E (fr)
RU (1) RU2492167C2 (fr)
SI (1) SI2225231T1 (fr)
TW (1) TWI434685B (fr)
WO (1) WO2009077990A1 (fr)
ZA (1) ZA201005080B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
SI2432760T1 (sl) * 2009-05-18 2013-10-30 Actelion Pharmaceuticals Ltd. Premoĺ äśeni derivati spiro (2.4) heptana kot alx-receptorji in/ali fprl2-agonisti
BRPI1010738A8 (pt) 2009-06-09 2017-12-26 Actelion Pharmaceuticals Ltd Derivados de aminotriazol fluorado
JP5624130B2 (ja) * 2009-06-12 2014-11-12 アクテリオンファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ａｌｘ受容体アゴニストとしてのオキサゾール及びチアゾール誘導体
WO2012066488A2 (fr) 2010-11-17 2012-05-24 Actelion Pharmaceuticals Ltd Dérivés à ponts ester de spiro [2.4] heptane
MX2013006420A (es) 2010-12-07 2013-07-29 Actelion Pharmaceuticals Ltd Derivados de aminotriazol hidrolixado como agonistas del receptor de alx.
ES2526132T3 (es) * 2010-12-07 2015-01-07 Actelion Pharmaceuticals Ltd. Derivados de oxazolil-metiléter como agonistas del receptor de ALX
EP2707373A1 (fr) 2011-05-10 2014-03-19 Bayer Intellectual Property GmbH (thio)carbonylamidines bicycliques
EP2739143B1 (fr) * 2011-08-05 2018-07-11 Gary A. Flynn Préparation et procédés d'utilisation d'ortho-aryle hétéroaryle à 5 chaînons -carboxamide contenant des inhibiteurs de kinases multicibles
CN102558117B (zh) * 2011-12-15 2014-10-08 北京金骄生物质化工有限公司 一种利用废弃生物质制备5-硝基-2-糠酸酯的方法
EP2850058B1 (fr) 2012-05-16 2016-07-13 Actelion Pharmaceuticals Ltd. Dérivés de 1- (p-tolyl) cyclopropyl substituted bridged spiro [2,4] heptane en tant qu' agonistes du récepteur alx.
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
KR101689093B1 (ko) 2012-06-04 2016-12-22 액테리온 파마슈티칼 리미티드 벤즈이미다졸-프롤린 유도체
JP6244365B2 (ja) 2012-10-10 2017-12-06 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ［オルトビ−（ヘテロ−）アリール］−［２−（メタビ−（ヘテロ−）アリール）−ピロリジン−１−イル］−メタノン誘導体であるオレキシン受容体アンタゴニスト
JP2016505550A (ja) * 2012-12-03 2016-02-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 置換トリアゾール及びイミダゾール化合物
CN105051040A (zh) 2013-03-12 2015-11-11 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物
AR096686A1 (es) 2013-06-25 2016-01-27 Actelion Pharmaceuticals Ltd Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx
AU2014292064B2 (en) 2013-07-18 2018-07-05 Idorsia Pharmaceuticals Ltd Piperazine substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
EP3075726B1 (fr) 2013-11-28 2017-11-08 Kyorin Pharmaceutical Co., Ltd. Dérivés d'urée ou leurs sels pharmacologiquement acceptables en tant qu'agonistes du récepteur fprl-1
MX366642B (es) 2013-12-04 2019-07-17 Idorsia Pharmaceuticals Ltd Uso de derivados de bencimidazol-prolina.
CA2987235A1 (fr) 2015-05-27 2016-12-01 Kyorin Pharmaceutical Co., Ltd. Derive de l'uree ou sel pharmacologiquement acceptable de ce dernier
WO2016189877A1 (fr) 2015-05-27 2016-12-01 Kyorin Pharmaceutical Co., Ltd. Dérivé d'urée ou sel pharmacologiquement acceptable de ce dernier
CA3006291A1 (fr) * 2015-11-24 2017-06-01 Bristol-Myers Squibb Company Ciblage du recepteur 2 de peptide formyle / du recepteur de la lipoxine a4 (fpr2/alx) pour le traitement de maladies cardiaques
KR102803660B1 (ko) 2018-03-05 2025-05-02 브리스톨-마이어스 스큅 컴퍼니 페닐피롤리디논 포르밀 펩티드 2 수용체 효능제
US11629143B2 (en) 2020-10-01 2023-04-18 Vibliome Therapeutics, Llc HipK4 inhibitors and uses thereof
JP7743010B2 (ja) * 2021-03-12 2025-09-24 国立大学法人 長崎大学 ハロカルボニル化合物の製造方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62234018A (ja) 1986-04-02 1987-10-14 Rooto Seiyaku Kk 糖尿病併発症治療剤
WO2003035006A2 (fr) 2001-10-26 2003-05-01 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Amyloide $g(b), ligand des recepteurs de la classe fpr
WO2003082314A2 (fr) 2002-04-03 2003-10-09 Bayer Healthcare Ag Diagnostics et therapies pour maladies liees a un recepteur de type 1 de peptides n-formyl (fprl1)
JP2007516434A (ja) * 2003-11-07 2007-06-21 アカディア ファーマシューティカルズ インコーポレイティド リポキシン受容体ｆｐｒｌ１の、疼痛および炎症の治療に有効な化合物を識別する手段としての使用
EP1751120A4 (fr) * 2004-05-25 2010-05-05 Metabolex Inc Triazoles substitués comme modulateurs de ppar et méthodes de préparation
ZA200704809B (en) * 2004-12-13 2008-08-27 Leo Pharma A S Triazole substituted aminobenzophenone compounds
AU2006312083A1 (en) * 2005-11-03 2007-05-18 Merck Sharp & Dohme Corp. Histone deacetylase inhibitors with aryl-pyrazolyl motifs
JP2009535393A (ja) * 2006-05-01 2009-10-01 ファイザー・プロダクツ・インク 置換２−アミノ縮合複素環式化合物
CN101828111B (zh) 2007-08-21 2014-07-23 塞诺米克斯公司 人t2r苦味受体及其用途
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
SI2432760T1 (sl) 2009-05-18 2013-10-30 Actelion Pharmaceuticals Ltd. Premoĺ äśeni derivati spiro (2.4) heptana kot alx-receptorji in/ali fprl2-agonisti
BRPI1010738A8 (pt) 2009-06-09 2017-12-26 Actelion Pharmaceuticals Ltd Derivados de aminotriazol fluorado
JP5624130B2 (ja) 2009-06-12 2014-11-12 アクテリオンファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ａｌｘ受容体アゴニストとしてのオキサゾール及びチアゾール誘導体

Also Published As

Publication number Publication date
AU2008337097A1 (en) 2009-06-25
EP2225231B1 (fr) 2011-08-17
BRPI0821115A8 (pt) 2017-12-26
WO2009077990A1 (fr) 2009-06-25
AR069801A1 (es) 2010-02-17
RU2492167C2 (ru) 2013-09-10
MY153985A (en) 2015-04-30
CN101903378B (zh) 2014-03-12
CY1112465T1 (el) 2015-12-09
CN101903378A (zh) 2010-12-01
US20100331378A1 (en) 2010-12-30
TWI434685B (zh) 2014-04-21
HK1144158A1 (en) 2011-01-28
BRPI0821115A2 (pt) 2015-06-16
TW200932216A (en) 2009-08-01
IL206399A (en) 2016-03-31
ATE520689T1 (de) 2011-09-15
US8536209B2 (en) 2013-09-17
CA2706839C (fr) 2015-10-20
PT2225231E (pt) 2011-10-19
ZA201005080B (en) 2011-12-28
RU2010129272A (ru) 2012-01-27
MX2010006241A (es) 2010-06-30
HRP20110825T1 (hr) 2011-12-31
CA2706839A1 (fr) 2009-06-25
JP2011506594A (ja) 2011-03-03
IL206399A0 (en) 2010-12-30
SI2225231T1 (sl) 2011-12-30
PL2225231T3 (pl) 2012-01-31
KR20100092516A (ko) 2010-08-20
JP4656674B2 (ja) 2011-03-23
EP2225231A1 (fr) 2010-09-08
DK2225231T3 (da) 2011-10-17
AU2008337097B2 (en) 2014-03-20
KR101213007B1 (ko) 2012-12-20
NZ586735A (en) 2012-06-29

Similar Documents

Publication Publication Date Title
MA31949B1 (fr) Dérivés d'aminotriazole comme agonistes d'alx
MA33365B1 (fr) Dérivés de spiro[2.4]heptane pontés utiles en tant qu'agonistes du récepteur de alx et/ou du récepteur fprl2
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA30207B1 (fr) Modulateurs des recepteurs de la progesterone a base d'indole sulfonamide
MA27427A1 (fr) Composes de benzimidazole-1-yl-thiophene utilises en cancerotherapie
TN2010000230A1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA31683B1 (fr) Composes et procedes pour moduler fxr
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
MA27647A1 (fr) Antagonistes de ccr5 utiles comme agents therapeutiques
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA31766B1 (fr) Composés organiques
MA32655B1 (fr) Composés modulant sélectivement le récepteur cb2
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA29378B1 (fr) Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA27728A1 (fr) Antagonistes des recepteurs de cgrp
MA29213B1 (fr) Quinolones a substitution macrolones - amino
MA29685B1 (fr) Composes spiroheterocycliques et leurs utilisations en tant qu'agents therapeutiques
TN2009000324A1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoides
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda